EU Approves Abbott's Humira For Ulcerative Colitis Use

Law360, New York (April 11, 2012, 7:32 PM EDT) -- The European Commission has approved Abbott Laboratories' blockbuster anti-inflammatory drug Humira for treatment of adult ulcerative colitis, the company said Wednesday, further expanding the uses of the pharmaceutical giant’s top-selling drug.

Abbott said the approval makes Humira the only self-injectable biologic therapy for the treatment of moderately to severely active ulcerative colitis, and the seventh different use approved by the EC since the drug was first approved in 2003. The approval was based on two clinical trials involving more than 800 patients in 21 countries, the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.